期刊文献+

EP4受体拮抗剂对激素非依赖性前列腺癌DU145细胞恶性表型的影响 被引量:2

Effects of EP4 receptor antagonist on the malignant phenotypes of androgen-independent prostate cancer DU145 cells
下载PDF
导出
摘要 目的 EP4受体与肿瘤的发生、发展关系密切,文中旨在探讨EP4受体拮抗剂对激素非依赖性前列腺癌(androgen-independent prostate cancer,AIPC)细胞的体外抗肿瘤效应。方法利用RT-PCR和Western blot检测DU145细胞中EP4受体mRNA及蛋白的表达水平。采用MTT比色法、划痕愈合实验、细胞侵袭实验观察ONO-AE3-208对AIPC DU145细胞增殖、迁移和侵袭能力的抑制效应。用已知EP4极低水平表达的LNCaP/mock和LNCaP细胞作为对照组,DU145细胞作为实验组。结果 RT-PCR及Western blot结果显示,DU145细胞中EP4受体mRNA表达水平较对照的LNCaP和LNCaP/mock细胞分别高出4.698倍和8.137倍,EP4受体蛋白也呈现高水平表达。MTT比色法结果显示随ONO-AE3-208作用时间和浓度的增加,其对DU145细胞增殖的影响不明显(P>0.05);划痕愈合实验结果提示:经10μmol/L ONO-AE3-208作用24h,DU145细胞的细胞迁移率[(16.231±4.112)%]明显低于对照组[(48.710±7.219)%](P<0.01)。细胞侵袭实验结果提示:经0.1、1.0和10.0μmol/LONO-AE3-208作用24 h,实验组DU145细胞穿入下室细胞数[分别为(27.4±4.5)、(18.6±4.0)、(13.6±5.0)个]明显少于对照组[(38.8±5.2)个],差异有统计学意义(P<0.05)。结论 EP4受体在AIPC DU145细胞中表达明显升高。EP4受体拮抗剂ONO-AE3-208对AIPC DU145的增殖无影响,对其迁移和侵袭能力有明显的抑制作用。 Objective The EP4 receptor is proved to be closely related to the development and progression of cancer.This study is to examine the anti-tumor effects of the EP4 antagonist on androgen-independent prostate cancer (AIPC) DU145 cells in vitro.Methods We detected the expression levels of EP4 mRNA and protein in the DU145 cells by quantitative real-time PCR and Westernblot,and observed the inhibitory effect of the EP4 antagonist ONO-AE3-208 on the proliferation of the AIPC DU145 cells by MTT,wound-healing test,and Transwell invasion assay,with the known extremely lowly expressed LNCaP and LNCaP/mock cells as the control.Results Quantitative real-time PCR showed that the expression level of EP4 mRNA in the DU145 cells was 4.698 and 8.137 times higher respectively than those in the LNCaP and LNCaP/mock cells,and the EP4 protein was also highly expressed.The EP4 antagonist ONO-AE3-208 exhibited no significant time-and concentration-dependent influence on the proliferation of the DU145 cells (P 〉0.05).After treated with ONO-AE3-208 at 10 μmol/L for 24 hours,the DU145 cells showed a marked lower rate of migration than the control ([16.231 ±4.112]% vs [48.710 ±7.219]%,P 〈 0.01).After 24-hour intervention with ONO-AE3-208 at 0.1,1.0,and 10 μmol/L,the numbers of the DU145 cells that had invaded the inferior chamber were 27.4 ±4.5,8.6 ±4.0,and 13.6 ± 5.0 respectively,significantly lower than 38.8 ± 5.2 in the control group (P 〈 0.05).Conclusion The EP4 receptor is highly expressed in AIPC DU145 cells.The EP4 antagonist ONO-AE3-208 does not affect the proliferation of the DU145 cells,but can significantly inhibit their migration and invasion abilities.
出处 《医学研究生学报》 CAS 北大核心 2014年第5期460-463,共4页 Journal of Medical Postgraduates
基金 国家自然科学基金(81372742)
关键词 EP4受体 前列腺癌 恶性表型 EP4 receptor Prostate cancer Malignant phenotype
  • 相关文献

参考文献14

  • 1许松,周文泉,张征宇,葛京平,高建平.选择性环氧化酶2抑制剂塞来昔布对人前列腺癌PC-3细胞增殖与凋亡的影响[J].中华男科学杂志,2008,14(6):489-493. 被引量:7
  • 2Smith MR, Manola J, Kaufman DS, et al. Celecoxib versus pla- cebo for men with prostate cancer and a rising serum prostate-spe- cific antigen after radical prostatectomy and/or radiation therapy [J]. J Clin Oncol, 2006, 24(18) : 2723-2728.
  • 3Gupta S, Srivastava M, Ahmad N, et al. Over-expression ofcy- clooxygenase-2 in human prostate adenocarcinoma[ J ]. Prostate, 2000, 42(1) : 73-78.
  • 4Terada N, Shimizu Y, Kamba T, et al. Identification of EP4 as a potential target for the treatment of castration-resistant prostate Cancer using a novel xenograft model[ J]. Cancer Res, 2010, 70 (4) : 1606-1615.
  • 5Yoshimura R, Sano H, Masuda C, et al. Expression of cyclooxygen- ase-2 in prostate carcinoma[J]. Cancer, 2000, 89(3) : 589-596.
  • 6Chen Y, Hughes-Fulford M. Prostaglandin E2 and the protein ki- nase A pathway mediate arachidonic acid induction of c-los in hu- man prostate Cancer cells [ J ]. Br J Cancer, 2000, 82 ( 12 ) : 2000 -2006.
  • 7Sung YM, He G, Hwang DH, et al. Overexpression of the pros- taglandin E2 receptor EP2 results in enhanced skin tumor devel- opment[J]. Oncogene, 2006, 25(40): 5507-5516.
  • 8Kuo KT, Wang HW, Chou TY, et al. Prognostic role of PGE2 receptor EP2 in esophageal squamous cell carcinoma [ J ]. Ann Surg Oncol, 2009, 16(2) : 352-360.
  • 9Robertson FM, Simeone AM, Lucci A, et al. Differential regula- tion of the aggressive phenotype of inflammatory breast Cancer cells by prostanoid receptors EP3 and EP4 [ J]. Cancer, 2010, 116( 11 Suppl) : 2806-2814.
  • 10Risbridger GP, Davis ID, Birrell SN, et al. Breast and prostate Cancer: more similar than different[J]. Nat Rev Cancer, 2010, 10(3) : 205-212.

二级参考文献22

  • 1葛京平,徐锋,程文,杨斌,张春妮,高建平,张征宇,张庆玲,许传亮,孙颖浩.肾透明细胞癌相关特异性miRNAs差异表达谱[J].医学研究生学报,2011,24(8):789-794. 被引量:7
  • 2丁翔,严春寅,温端改,侯建全,浦金贤.COX-2、bcl-2和PCNA在前列腺癌中的表达及其意义[J].苏州大学学报(医学版),2005,25(1):110-112. 被引量:10
  • 3刘浩,刘志勇.内皮素系统与肺动脉高压关系的研究进展[J].医学研究生学报,2006,19(4):373-376. 被引量:4
  • 4Liu XH, Kirschenhaum A, Lu A, et al stimulates prostatic intraepithelial neoplasia Prostaglandin E ( 2 ) cell growth through activation of the interleukin-6/GP130/STAT-3 signaling pathway [J]. Biochem Biophys Res Commun, 2002, 290( 1 ) : 249-255.
  • 5Shahedi K, Lindstrom S, Zheng SL, et al. Genetic variation in the COX-2 gene and the association with prostate cancer risk [ J ]. Int J Cancer, 2006, 119 (3) :668-672.
  • 6Hussain T, Gupta S, Mukhtar H. Cyclooxygenase-2 and prostate carcinogenesis[J]. Cancer Lett, 2003, 191(2): 125-135.
  • 7Narayanan BA, Reddy BS, Bosland MC, et al. Exisulind in combination with celecoxib modulates epidermal growth factor receptor, cyclooxygenase-2, and cyclin D1 against prostate carcinogenesis: in vivo evidence[J]. Clin Cancer Res, 2007, 13(19) : 5965 -5973.
  • 8Smith MR, Manola J, Kaufman DS,et al. Celecoxib versus placebo for men with prostate cancer and a rising serum prostate-specific antigen after radical prostatectomy and/or radiation therapy [J]. JClinOncol, 2006, 24(18) :2723-2728.
  • 9Pruthi RS, Derksen JE, Moore D,et al. Phase Ⅱ trial of celecoxib in prostate-speeific antigen recurrent prostate cancer after definitive radiation therapy or radical prostatectomy[ J]. Clin Cancer Res, 2006, 12(7 Pt 1 ) :2172-2177.
  • 10Caries J, Font A, Mellado B, et al. Weekly administration of docetaxel in combination with estramustine and eelecoxib in patients with advanced hormone-refractory prostate cancer: final results fromaphase Ⅱ study[J]. Br J Cancer, 2007, 97(9): 1206- 1210.

共引文献13

同被引文献4

引证文献2

二级引证文献5

相关作者

内容加载中请稍等...

相关机构

内容加载中请稍等...

相关主题

内容加载中请稍等...

浏览历史

内容加载中请稍等...
;
使用帮助 返回顶部